Abstract: The present invention relates to, inter alia, a composition, a nanocomposite material, and a method for preparing the nanocomposite material. The nanocomposite material includes: a dielectric-silver nanocomposite material, the dielectric-silver nanocomposite material including a silver nanoparticle having a silver ion, and a dielectric material encapsulating the silver nanoparticle, where the silver ion chelates with a matrix of the dielectric material, and a surface plasmon band absorption of the dielectric-silver nanocomposite material lies outside a range of a visible region.

Abstract: An aminosiloxane polymer includes at least one Si-bonded functional group. This functional group has the chemical formula: —(R—NH)aR1—N(R2)—CH(—COOH)(—R3—C(?O)—NR42) (I). In Formula (I), R is a C1-C10 hydrocarbon group. R1 is a C1-C10 hydrocarbon group. R2 is a hydrogen atom, a C1-C12 hydrocarbon group, or a phenyl group. R3 is a C1-C4 hydrocarbon group. Each R4 is independently a hydrogen atom, a C1-C12 hydrocarbon group, a C1-C12 hydroxyl-hydrocarbon group, or a phenyl group. Moreover, “a” is 0 or 1, such that (R—NH) is optional. The aminosiloxane polymer can be formed using the method of this disclosure and can be formed in, and/or included in, the emulsion of this disclosure.

Abstract: A multi-layer product for improving the look of human skin by the steps of: apply to the skin a first layer that is a skin care composition; and applying to, and on top of, the first layer, a powder layer. The powder layer has from about 10% to about 30%, by weight of the powder layer, of substantially spherical particles selected from the group consisting of coated or uncoated starch, silicone elastomer particles, and combinations thereof. The powder layer is an aqueous based composition that is an oil-in-water emulsion comprising a non-volatile oil present in a concentration level such that the weight ratio of non-volatile oil to particulate material is from about 1:10 to about 3:2. At least one of, or both the first layer and the powder layer have a contrast ratio of less than about 20.

Abstract: Process for making a conditioning gel phase comprising: i) forming an aqueous dispersion of fatty alcohol and amidoamine; ii) adding a cationic surfactant to the aqueous dispersion and mixing; and iii) neutralizing the amidoamine, wherein the temperature of the mixture of cationic surfactant in the aqueous dispersion is maintained at from 56° C. to 67° C.

Abstract: The proposed compositions and methods for preparation thereof relate to pharmacology, medicine, veterinary science and pharmaceutical industry. The compositions can be used for preparing infusion solutions of antimicrobial (antibacterial and antifungal) preparations increasing therapeutic efficiency thereof. The compositions include nanostructured colloidal silica and are efficient when treating overwhelming sepsis of tested animals, provoked by Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa and Candida albicans. The pharmaceutical compositions have a proven and significant clinically important potentiating impact on therapeutic efficiency of the infusion solutions, when treating inflammatory diseases, in comparison with traditional solvents.

Abstract: One embodiment described herein is related to methods and compositions, such as nutraceutical formulations and dietary supplements, comprising C16:1n7-palmitoleate or derivatives thereof. The methods and compositions comprising C16:1n7-palmitoleate, or derivatives thereof, safely and effectively prevent or mitigate manifestations of cardiovascular disease, including coronary artery disease and the accumulation of cholesterol or lipid deposits in the blood vessels of a subject.

Abstract: The present invention provides a compound of a formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD).

Abstract: A nanoemulsion having reversible continuous and dispersed phases. The nanoemulsion includes an aqueous phase and an oil phase, a weight ratio of the aqueous phase to the oil phase being 1:40-100:1. In the nanoemulsion, the aqueous phase is dispersed as nanosized droplets in the oil phase or the oil phase is dispersed as nanosized droplets in the aqueous phase. The aqueous phase contains water or a water solution and a water-soluble organic nanostructure stabilizer. The oil phase contains an oil or an oil solution, an organic gel thickener, and a hydrophilic surfactant having a hydrophilic-lipophilic balance value greater than 8.0. Also disclosed is a method for preparing the above-described nanoemulsion.

Abstract: One embodiment described herein is related to methods and compositions, such as nutraceutical formulations and dietary supplements, comprising C16:1n7-palmitoleate or derivatives thereof. The methods and compositions comprising C16:1n7-palmitoleate, or derivatives thereof, safely and effectively prevent or mitigate manifestations of cardiovascular disease, including coronary artery disease and the accumulation of cholesterol or lipid deposits in the blood vessels of a subject.

Abstract: The invention relates to bars which provide specific combinations and amounts of nonionic polymer, polyol, short chain fatty acid and solid particles. These specific combinations provide both improved sensory and improved fragrance delivery.

Abstract: A transdermal composition comprising ibuprofen or salts thereof and a gelling agent which can be used for the treatment of such disorders as pain, inflammation, arthritis, muscle spasm and associated symptoms in humans and animals.

Abstract: Disclosed are nutritional formulations including predigested fats that can be administered to preterm infants, infants, toddlers, and children for improving tolerance, digestion, and absorption of nutrients and for reducing the incidence of necrotizing enterocolitis, colic, and short bowel syndrome. The predigested fats include fatty acid-containing monoglycerides and/or a fatty acid component.

Abstract: The proposed compositions and methods for preparation thereof relate to pharmacology, medicine, veterinary science and pharmaceutical industry. The compositions can be used for preparing infusion solutions of antimicrobial (antibacterial and antifungal) preparations increasing therapeutic efficiency thereof. The compositions include nanostructured colloidal silica and are efficient when treating overwhelming sepsis of tested animals. The pharmaceutical compositions have a proven and significant clinically important potentiating impact on therapeutic efficiency of the infusion solution, when treating inflammatory diseases, in comparison with traditional solvents.

Abstract: The present invention provides aqueous alkaline, storage stable, abrasive containing hard surface treatment compositions which provide good cleaning to a treated hard surface, and concurrently a useful sanitizing or disinfecting benefit to such treated surfaces, wherein the compositions comprise: 0.01-15% wt. of at least one anionic surfactant and at least one nonionic surfactant, and preferably wherein the amount of the at least one anionic surfactant is in excess of the amount of the at least one nonionic surfactant; 0.1-50% wt. of one or more inorganic abrasive particulate materials which are based on inorganic carbonate compounds; a thickener; at least one non-cationic germicide constituent, which preferably are one or more compounds selected from the group consisting of: parachlorometaxylenol, and halogenated carbanilides (e.g.

Abstract: The present invention relates to transdermal therapeutic systems that include an occlusive back layer impervious to an active substance, a single or multilayer matrix, and a peelable protective film. The matrix or at least one of the matrix layers includes a pharmaceutical active substance or a plurality of pharmaceutical active substances in the form of at least one pharmaceutically consumable salt thereof and a pharmaceutically consumable, alkaline reacting oxide.

Abstract: A colloid or crystalline solution with the addition of poly-oxygenated metal hydroxide particles. The solution is configured to treat a condition of a mammal, including a human individual and an animal including a depletion of hemoglobin and hemorrhagic shock. The solution can be intravenously administered. In some embodiments, the poly-oxygenated metal hydroxide is an aluminum poly-oxygenated hydroxide, such as Ox66™. The poly-oxygenated metal hydroxide may have particles having a diameter of less than or equal to 1 um, and specifically having a diameter of less than or equal to 100 nm.

Abstract: The present invention relates to a pharmaceutical formulation comprising therapeutically effective amount of vildagliptin or pharmaceutically acceptable salt thereof and a diluent. Particularly, the ratio of vildagliptin to diluent is in the range of 0.04 to 0.24 (w/w).

Abstract: It is one of the objects of the present disclosure to provide hexagonal plate-shaped zinc oxide particles having suitable performances derived from the shape thereof, that is, zinc oxide particles having improved ultraviolet shielding ratio at the wavelength of 400 nm or less without impairing the direct transition properties of electronic excitation thereof and having remarkably improved ultraviolet shielding ratio for UV-B radiation and UV-A radiation. A zinc oxide particle containing a solid solution of a Ti element and/or a Fe element and a Zn element in at least a portion thereof, and having a hexagonal plate shape.

Abstract: Technologies are generally described for a method and compounds for managing dag on hair. The method of managing dag on hair includes applying a low energy compound including a silicone and a terminal reactive group to the hair and applying a hair binding moiety to the hair for functionalizing the low energy compound, at its terminal reactive group, to bind to the hair. The applied low energy compound enables ease of removal of dag from the hair or mitigation of dag formation on the hair. The functionalized low energy compound may be made prior to the application to the hair.

Abstract: The invention relates to a pharmaceutical film formulation comprising one or more bitter-tasting drug(s) or pharmaceutically acceptable salts thereof, one or more film formers, a bitterness masker containing one or more inorganic and/or organic salt(s) and at least two monocyclic monoterpenes, and one or more sweetening agents.